Aura Biosciences Stock Falls After Eye-Cancer Trial News
Aura Biosciences shares fell 4.2% to $6.89 Tuesday after the company announced it completed enrollment of 108 patients in its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma. Topline results are expected in the second half of 2027. The company reported $114.7 million in cash at the end of March and raised $280.8 million more in a recent equity sale. Aura has no approved products and relies on bel-sar for future growth.